We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+5.02%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$500M
AUM Growth
-$115M
Cap. Flow
-$85.2M
Cap. Flow %
-17.03%
Top 10 Hldgs %
48.26%
Holding
330
New
47
Increased
56
Reduced
65
Closed
116

Top Buys

Rank Stock Value
1
ZLAB icon
Zai Lab
ZLAB
+$14.3M
2
IKT icon
Inhibikase Therapeutics
IKT
+$12.7M
3
BIL icon
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
+$10.1M
4
ABVX
Abivax
ABVX
+$9.13M
5
RVMD icon
Revolution Medicines
RVMD
+$6.34M

Top Sells

Rank Stock Value
1
RPRX icon
Royalty Pharma
RPRX
+$27.8M
2
CYTK icon
Cytokinetics
CYTK
+$25.8M
3
KROS icon
Keros Therapeutics
KROS
+$21.9M
4
BBIO icon
BridgeBio Pharma
BBIO
+$19.9M
5
ASND icon
Ascendis Pharma A/S
ASND
+$11.8M

Sector Composition

Rank Sector Weight
1 Healthcare 77.69%
2 Financials 3.07%
3 Communication Services 1.32%
4 Technology 0.33%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVO
276
PUT
Novo Nordisk
NVO
$209B
– –
-20,000
Closed -$2.38M
OAKU
277
DELISTED
Oak Woods Acquisition Corp
OAKU
– –
-30,000
Closed -$333K
OPCH icon
278
Option Care Health
OPCH
$3.56B
– –
-20,000
Closed -$626K
PCVX icon
279
Vaxcyte
PCVX
$8.64B
– –
-10,097
Closed -$1.15M
PHGE icon
280
BiomX
PHGE
$1.85M
– –
-22,774
Closed -$441K
PHVS icon
281
Pharvaris
PHVS
$2.44B
– –
-2,000
Closed -$37K
PRGO icon
282
Perrigo
PRGO
$1.78B
– –
-1,000
Closed -$26.2K
PRM icon
283
Perimeter Solutions
PRM
$5.77B
– –
-9,000
Closed -$121K
PRTC
284
DELISTED
PureTech Health
PRTC
– –
-3,000
Closed -$61.8K
RNAM
285
DELISTED
Avidity Biosciences
RNAM
– –
-600
Closed -$27.6K
SAGE
286
CALL
DELISTED
Sage Therapeutics
SAGE
– –
-9,500
Closed -$68.6K
SNDX icon
287
CALL
Syndax Pharmaceuticals
SNDX
$1.82B
– –
-105,000
Closed -$2.02M
SNDX icon
288
Syndax Pharmaceuticals
SNDX
$1.82B
– –
-350,206
Closed -$6.74M
SWTX
289
DELISTED
SpringWorks Therapeutics
SWTX
– –
-100
Closed -$3.2K
SYRE icon
290
Spyre Therapeutics
SYRE
$9.25B
– –
-12,560
Closed -$369K
TARS icon
291
Tarsus Pharmaceuticals
TARS
$2.84B
– –
-25,900
Closed -$1.18M
TERN
292
DELISTED
Terns Pharmaceuticals
TERN
– –
-24,702
Closed -$206K
TGTX icon
293
TG Therapeutics
TGTX
$7.62B
– –
-5,000
Closed -$117K
TGTX icon
294
PUT
TG Therapeutics
TGTX
$7.62B
– –
-1,000
Closed -$23.4K
TH icon
295
Target Hospitality
TH
$1.64B
– –
-65,741
Closed -$511K
TRIP icon
296
TripAdvisor
TRIP
$1.26B
– –
-4,000
Closed -$58K
TRML
297
DELISTED
Tourmaline Bio
TRML
– –
-11,260
Closed -$289K
TXG icon
298
10x Genomics
TXG
$6.61B
– –
-15,000
Closed -$339K
UCTT
299
Ultra Clean Holdings
UCTT
$3.95B
– –
-1,000
Closed -$39.9K
YARW
300
Yarrow Bioscience, Inc. Common Stock
YARW
$111M
– –
-3,057
Closed -$287K
10 11
12
13 14

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, ADAR1 Capital Management held 330 positions worth $500M, down 19% from $615M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

ADAR1 Capital Management withdrew a net $85.2M in Q4 2024, closing 116 positions and reducing 65 holdings. Its most notable exit was Syndax Pharmaceuticals, an estimated $6.74M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 86% a quarter earlier, followed by Financials and Communication Services.

Against the trend, ADAR1 Capital Management opened a new position in Inhibikase Therapeutics worth $16.6M.

  • ADAR1 Capital Management's largest Q4 2024 buy was Inhibikase Therapeutics: 5,103,005 shares worth $16.6M.
  • ADAR1 Capital Management added most to Zai Lab in Q4 2024, an estimated $14.3M increase.
  • ADAR1 Capital Management's biggest Q4 2024 reduction was Royalty Pharma, cutting an estimated $27.8M.
  • ADAR1 Capital Management fully exited Syndax Pharmaceuticals in Q4 2024, selling an estimated $6.74M.
  • ADAR1 Capital Management's ten largest holdings make up 48% of its $500M portfolio in Q4 2024.
  • ADAR1 Capital Management opened 47 new positions and closed 116 in Q4 2024.
  • ADAR1 Capital Management's portfolio value fell 19% quarter-over-quarter to $500M.

Based on ADAR1 Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.